Introduction:
Daiichi Sankyo with an investment of US$1.12 billion (€1 billion) plans to expand production and development site in Pfaffenhofen an daer Ilm in Germany.
Features:
The Pfaffenhofen facility is recognised globally as a leading site for producing clinical products. New analysis methods, crucial for maintaining quality standards, are carefully developed within the analytical department.
These methods are crafted within the analytical department and later employed in quality control processes to thoroughly assess the final medicinal products.
The opening of a new building in late 2023 offered sufficient space to accommodate both departments, reflecting a committed endeavour to enhance efficiency and accuracy in production.
In addition to boosting production for cardiovascular diseases, new labs are specifically designed for antibody drug conjugate technology (ADC). These labs will focus on developing and producing innovative cancer therapies for breast, lung, and stomach cancers.
The expansion also involves hiring top-notch international researchers, process engineers, and other experts in sterile and biotechnology fields.
This expansion project has already commenced and is slated for completion no later than 2030.
Specifications:
Name Daiichi Sankyo
Type New Construction
Budget US$1.12 billion (€1 billion)
Year 2030
